Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent? (Q36254990)

13 August 2017

1 reference

title

Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent? (English)

1 reference

13 August 2017

1 reference

2

Isabelle Coupier

1 reference

13 August 2017

3

Pascal Pujol

1 reference

13 August 2017

Mehadad Noruzinia

1

1 reference

PubMed ID

16155942

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

104

1 reference

13 August 2017

8

1 reference

13 August 2017

1567-1574

1 reference

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

13 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Breast cancer and hormone-replacement therapy: the Million Women Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Postmenopausal hormone replacement therapy: scientific review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Breast cancer prevention—clinical trials strategies involving aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Polygenic susceptibility to breast cancer and implications for prevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

How many more breast cancer predisposition genes are there?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Cancer susceptibility and the functions of BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

BRCA1: the enigma of tissue-specific tumor development.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Anti-oestrogenic prevention of breast cancer--the make or break point

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Rising levels of estrogen receptor in breast cancer over 2 decades

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Selective estrogen receptor modulators: structure, function, and clinical use.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

BRCA1 expression levels predict distant metastasis of sporadic breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Role of direct interaction in BRCA1 inhibition of estrogen receptor activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Puberty and genetic susceptibility to breast cancer in a case-control study in twins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

BRCA1 expression is not directly responsive to estrogen.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Structural determinants of the BRCA1 : estrogen receptor interaction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21367

7 January 2021

Identifiers

DOI

10.1002/CNCR.21367

1 reference

13 August 2017

1 reference

PubMed ID

16155942